Lipiodol uptake and retention by human hepatoma cells

Chou, Fong‐In; Fang, Kang; Chung, C.‐S.; Lui, Wing‐Yiu; Chi, Chen‐Ta; Liu, R.S.; Chan, Wing Kai

doi:10.1016/0969-8051(94)00112-w

Cited by 35 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatoma cells are characterized by selective active uptake of lipiodol and prolonged intracellular retention for their life-span [3].…”

Section: Discussionmentioning

confidence: 99%

“…PEI is generally performed for HCC from 3-5 cm in diameter, although acceptable results have been attained in larger tumors [2]. HCC cells are characterized by lipiodol deposition (an ethyl Ester of fatty acid of poppy seed containing 37-39% iodine by weight) and emulsification on cell surface, active uptake of lipiodol and prolonged intra-cellular retention for their life span [3]. For percutaneous ethanol lipiodol injection therapy the mixture of 99.5% ethanol and lipiodol at a ratio 10:1 was used with better results than ethanol alone [4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Ethanol Lipiodol Injection Therapy versus Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma

Darweesh¹

2016

GHOA

View full text Add to dashboard Cite

Background & aim: Percutaneous ethanol injection (PEI) has become one of the most widely used procedures for treatment of hepatocellular carcinoma (HCC) up to 5 cm. PEI is occasionally ineffective due to in homogenous distribution within tumor while percutaneous ethanol lipiodol injection therapy (PELIT) is useful irrespective of vasculature, as HCC cells are characterized by selective, active uptake of lipiodol. The primary outcome was the higher success rate of PELIT with fewer sessions in comparison to RFA in HCC. Patients and methods:A prospective study was conducted on 43 patients with HCC, 27 of them under went PELIT & 16 underwent RFA. Both groups had biopsy after one week and lesions with partial necrosis underwent additional PELIT or RFA respectively. Triphasic MRI and CT were performed one month after the end of sessions of PELIT and RFA respectively.Results: Tru-cut biopsy revealed complete necrosis in 17 (81%) patients of PELIT and 11(68.7%) patients of RFA group. Six patients of PELIT group were not biopsied due to non-visible lesions by ultrasound, ascites or low PC. After additional sessions (in partial necrosis), triphasic MRI for PELIT group showed non-enhancement in 26(92.3%) patients and triphasic CT for RFA group showed non-enhancement in 15 (93.6%) patients and one patient in each group showed peripheral enhancement. Conclusion:PELIT is safe & effective for treatment of HCC, the number of sessions are equal to the diameter of HCC in cm (fewer sessions than RFA or PEI alone). PELIT can be performed for cases liable or contraindicated to RFA. Triphasic MRI is the standard for follow up of cases of PELIT.

show abstract

“…Hepatoma cells are characterized by selective active uptake of lipiodol and prolonged intracellular retention for their life-span [3].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Percutaneous Ethanol Lipiodol Injection Therapy versus Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma

Darweesh¹

2016

GHOA

View full text Add to dashboard Cite

show abstract

“…Having passed the vascular barrier, the lipids accumulate on the surfaces of the tumor cells, as observed both in vitro and in vivo [7,[55][56]. Based on in vitro studies, membrane-bound droplets of LIP are thought to enter the cell via pinocytosis (fluid endocytosis) [45,[55][56][57][58].…”

Section: The Fate Of Lip In Hepatic Extracellular and Intracellular Tissuementioning

confidence: 99%

“…Based on in vitro studies, membrane-bound droplets of LIP are thought to enter the cell via pinocytosis (fluid endocytosis) [45,[55][56][57][58]. After resection of HCC tumors in patients treated with a LIP-cytostatic agent emulsion, LIP was found in both the vascular lumen and the endothelial cells of the tumors [45].…”

Section: The Fate Of Lip In Hepatic Extracellular and Intracellular Tissuementioning

confidence: 99%

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

Dubbelboer

Lilienberg

Ahnfelt

et al. 2014

Therapeutic Delivery

View full text Add to dashboard Cite

The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho)physiology. These two DDSs, doxorubicin emulsified with Lipiodol ® and doxorubicin loaded into DC Bead ® are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.The global incidence of liver cancer is increasing and this type of cancer has a poor prognosis and is ranked as the third most common lethal cancer form [1,2]. The recommended treatment for hepatocellular carcinoma (HCC), a primary liver cancer, is dependent on the stage of the disease [3]. For unresectable, intermediate stage HCC, transarterial chemoembolization (TACE) is recommended. TACE involves the delivery of the cytostatic agent(s) in a drug-delivery system (DDS) to the tumor via the hepatic artery (HA) [3]. In contrast to normal liver tissue, which has a dual blood supply from the HA and the portal vein [4], HCC is typically mainly vascularized by the HA. Local drug administration by the TACE DDS is expected to increase the specificity of the tumor response while reducing the frequency of side effects and morbidity compared with systemic dosed treatments [4]. Embolization, caused by the DDS, obstructs the blood flow in the tumor, induces hypoxia, and results in increased drug concentrations and prolonged residence times in the tumortarget area [4]. Patients with untreated HCC that has not invaded the portal vein or spread extrahepatically have an expected median survival of approximately 16 months. With current palliative TACE strategies, the expected median survival is prolonged by approximately 4 months [3].To date, several DDSs delivering various chemotherapeutic drug(s) and pharmaceutical excipients have been developed and clinically evaluated for TACE therapy [5]. A review of these options of TACE DDSs is warranted in that it would form the basis for optimizing tumor-targeted therapy for HCC treatment, and subsequent development of novel, tumor-targeted DDSs and dosing strategies. Two common DDSs used for TACE therapy for intermediate stage HCC involve cytostatic agents emulsified in Lipiodol ® (LIP) or loaded into drugeluting beads. LIP is an iodized poppy seed oil derivative visible on x-ray, and after administration, the contrast is preferentially retained in tumor tissue [6,7]. The combination of the cytostatic agent emulsified in LIP can be administered with or without additional embolizing materials, generating complete or partial embolization of the targeted tumor-feeding vessel(s) [3,8]. DC Bead ® (DCB) is one of several commercially available drug-eluting embolizing bead systems [9]. Positively charged chemotherapeutic drugs can be ...

show abstract

“…The first chemoembolic agent used was iodinated poppy seed oil 81 , an excellent agent for intra-arterial embolization because of its viscosity and water insolubility. It causes occlusion of the downstream capillaries, has a more lethal effect on tumour cells than on hepatocytes, and is radiopaque, which allows for radiologic visualization during injection 81,82 . Iodinated poppy seed oil can be used in combination with multiple anticancer agents including cisplatin, doxorubicin, carboplatin, epirubicin, mitoxantrone, and mitomycin C 12 .…”

Section: Tacementioning

confidence: 99%

The Role of Interventional Radiology in the Management of Hepatocellular Carcinoma

Molla

Almenieir

Simoneau³

et al. 2014

Current Oncology

View full text Add to dashboard Cite

show abstract

Lipiodol uptake and retention by human hepatoma cells

Cited by 35 publications

References 23 publications

Percutaneous Ethanol Lipiodol Injection Therapy versus Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma

Percutaneous Ethanol Lipiodol Injection Therapy versus Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma

Treatment of Intermediate Stage Hepatocellular Carcinoma: A Review of Intrahepatic Doxorubicin Drug-Delivery Systems

The Role of Interventional Radiology in the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About